logo-loader
RNS
Kromek Group PLC

Kromek Group PLC - Delivery of Third Milestone and Grant of Options

RNS Number : 4814P
Kromek Group PLC
06 August 2026
 

6 August 2026

 

Kromek Group plc 

("Kromek" or the "Company" or the "Group") 

 

Delivery of third milestone under agreement with Siemens Healthineers

Grant of options to Directors

 

Kromek Group plc (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces the successful delivery of the third milestone under its enablement agreement (the "Enablement Agreement") with Siemens Medical Solutions USA, Inc. ("Siemens Healthineers") and the grant of options to directors of the Company.

 

Siemens Healthineers payment

 

Further to Kromek's announcement of 30 January 2025, the Company is pleased to announce that it has successfully delivered the third milestone under its Enablement Agreement with Siemens Healthineers and has received the third payment instalment of $2.5m. To date, the Company has received $32.5m under the Enablement Agreement. The remaining payment of $5.0m is payable at completion of the Group's delivery under the Enablement Agreement, which is expected to occur in the financial year to 30 April 2029.

 

Grant of options to directors

 

As detailed in the Company's final results announcement on 16 September 2025, Arnab Basu, CEO, and Berry Beumer, COO and President of the Advanced Imaging Division, were granted a special conditional bonus to be paid in four instalments dependent on the delivery of the four milestones under the Enablement Agreement, and the receipt by the Group of the associated cash payment, and subject to the individual remaining an employee of the Group. Dr. Basu and Mr. Beumer elected at that time to receive a significant proportion of the bonus as options over ordinary shares of 1p each ("Ordinary Shares") in the Company.

 

Accordingly, following the receipt of the third payment instalment under the Enablement Agreement, the Company granted, on 5 August 2026 (the "Grant Date"), Dr. Basu and Mr. Beumer 555,687 options each. The options vested upon issue and expire on the tenth anniversary of the Grant Date. The options have an exercise price of 1p per Ordinary Share and the number of options was calculated based on a price of 5.65p per Ordinary Share, being the average price of the Company's Ordinary Shares on AIM for the three months preceding and three months following the announcement of the Siemens Healthineers transaction on 30 January 2025.

 

Following this grant of options, the Company has options and long-term incentive awards outstanding over a total of 76,486,278 Ordinary Shares, representing 11.7% of the Company's issued share capital.

 

 

 

For further information, please contact: 

  

Kromek Group plc 


Arnab Basu, CEO 

Claire Burgess, CFO 

+44 (0)1740 626 060 

 


Cavendish Capital Markets Limited (Nominated Adviser and Broker)  

  

Geoff Nash/Giles Balleny/Seamus Fricker- Corporate Finance 

Andrew Burdis - ECM

Michael Johnson - Sales

+44 (0)20 7220 0500 

 



Gracechurch Group (Financial PR) 


Harry Chathli/Claire Norbury 

+44 (0)20 4582 3500 

 

 

Engage with the Kromek management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our interactive investor
hub here: https://investors.kromek.com/

 

Subscribe to our news alert service: https://investors.kromek.com/auth/signup

 

Kromek Group plc 

 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

 

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

 

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

 

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Arnab Basu

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Kromek Group plc

b)

 

LEI

 

 

213800VLHYXGHEX5VQ48

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Options over ordinary shares of 1 penny each



Identification code

GB00BD7V5D43



b)

 

Nature of the transaction

 

 

Grant of options

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




Exercise price of 1p

555,687







d)

 

 

Aggregated information

 

-      Aggregated volume

 

-      Price

 

 

N/A



e)

 

Date of the transaction

 

 

5 August 2026

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Berry Beumer

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Operating Officer and President of the Advanced Imaging Division

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Kromek Group plc

b)

 

LEI

 

 

213800VLHYXGHEX5VQ48

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Options over ordinary shares of 1 penny each



Identification code

GB00BD7V5D43



b)

 

Nature of the transaction

 

 

Grant of options

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




Exercise price of 1p

555,687







d)

 

 

Aggregated information

 

-      Aggregated volume

 

-      Price

 

 

N/A



e)

 

Date of the transaction

 

 

5 August 2026

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFITTAIEIIR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

6 min read